2Hadziyannis S,Tassopoulos N,Chang TT,et al.Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B patients in a long-term safety and efficacy study.J Hepatol,2004,40(Suppl 1):17 (Abstract 46).
3Hadziyannis SJ,Papatheodoridis GV.Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.Expert Rev Anti Infect Ther,2004,2:475-483.
4Marcellin P,Chang TT,Lim SG,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med,2003,348:808-816.
5Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.N Engl J Med,2003,348:800-807.
6Cullen JM,Li DH,Brown C,et al.Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.Antimicrob Agents Chemother,2001,45:2740-2745.
7Delmas J,Schorr O,Jamard C,et al.Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.Antimicrob Agents Chemother,2002,46:425-433.
8Werle-Lapostolle B,Bowden S,Locarnini S,et al.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.Gastroenterology,2004,126:1750-1758.
9Lok AS,McMahon BJ.Chronic hepatitis B:update of recommendations.Heptology,2004,39:857-861.
10Qi X,Snow A,Thibault V,et al.Long-term incidence of Adefovir Dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy.Hepatol,2004,40(Suppl 1):20 (Abstract 57).
4Lok AS,McMahon BJ.Chronic hepatitis B:update of recommendations.AASLD Practice Guideline[J].Hepatology,2004,39:857-861.
5Van Dame P and Van Herck K.A review of the efficacy immunogenicity and tolerability of a combined hepatitis A and B vaccine[J].Expert Rev Vaccines,2004,3:249-267.